 |
| CRS CEO Torben Thomsen |
German contract researcher CRS has inked a deal with Bayer, signing up to conduct Phase I and II trials for cardiovascular and women's health treatments.
The long-term deal builds upon an existing relationship between the two, CRS said, and under the new partnership CRS will take over some of Bayer's clinical pharmacology units, integrating them into its German research centers. In the process, the CRO will have expanded its clinical capabilities in cardiology and gynecology.
"We're very proud to have built up a relationship with Bayer HealthCare based on trust and proven performance, which will now be elevated to a strategic partnership," CEO Torben Thomsen said in a statement. "We welcome the new, highly qualified employees from Bayer HealthCare at the new sites who will help us expand our expertise in cardiovascular and gynecological indications and where we already plan to create new jobs."
For Bayer, cardiovascular and women's health drugs are among its largest targets for growth; the company has forged ahead with new studies to expand indications for Xarelto and a $1.1 billion buyout of Conceptus and its birth-control device.
Andernach-headquartered CRS employs about 280 at 8 labs across Germany, focusing largely on early-phase work but recently expanding into late-stage development, bioanalytics, data management and clinical trial supply.
- read the announcement